Inhibitors of t-darpp for use in combination anti-cancer therapies
AssigneeVanderbilt University
InventorsWael El-Rifai, Abbes Belkhiri
Life of this patent
Estimating the term…
Abstract
The present invention relates to an improved anti-HER2/Neu therapy comprising co-administration of an inhibitor of t-DARPP activity. In addition, inhibitors of t-DARPP can act as a monotherapy against cancers that express elevated t-DARPP activity, including elevated t-DARPP levels, or in combination with chemo- or radiotherapeutic anti-cancer treatments drugs.
Claims33
A method of improving the effect of an anti-HER2/Neu therapy in a subject comprising administering to said subject an inhibitor of t-DARPP activity.
A method of inhibiting trastuzumab resistance in a subject comprising administering to said subject an inhibitor of t-DARPP activity.
A method of inducing apoptosis in a cancer cell the overexpresses ERBB2 comprising contacting said cell with an anti-HER2/Neu agent and an inhibitor of t-DARPP activity.
A method of treating cancer in a subject comprising administering to said subject an anti-HER2/Neu therapy and an inhibitor of t-DARPP activity.
A method of inhibiting a cancer cell in a subject, wherein said cancer cell expresses elevated t-DARPP activity as compared to a comparable non-cancer cell, comprising administering to said subject an inhibitor of t-DARPP activity.
Dependencies are inferred from the claim text.